Jubilant Pharmova Limited has informed the Exchange about Other Restructuring
JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jubilant Pharmova's board approved the transfer of its Active Pharmaceutical Ingredients (API) business to Jubilant Biosys Limited (JBL), a wholly-owned subsidiary, on a slump sale basis. The API business contributed Rs. 609 crore in turnover (8.35% of consolidated revenue) and had a net worth of Rs. 666.5 crore (10.68% of consolidated net worth) for FY25. The deal was signed on June 12, 2025, and is expected to complete by September 1, 2025, subject to lender and shareholder approvals. The purchase consideration will be based on book value as of the appointed date (per Income Tax Rule 11UAE) and will be discharged primarily through issuance of shares by JBL. The move aims to house drug discovery and CDMO API services under one entity, creating an end-to-end CRDMO platform under the Jubilant Biosys brand.
Since the buyer is a wholly-owned subsidiary and consideration is paid mainly in shares, shareholders' overall economic interest remains unchanged — this is an internal restructuring rather than a true divestiture. Operational synergies and better asset utilisation are expected, but near-term stock reaction is likely to be neutral.